Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivastigmine - Novartis

Drug Profile

Rivastigmine - Novartis

Alternative Names: ENA 713; ENA 713D; Exelon; Exelon Patch; Exelon TDS; ONO-2540; Prometax; Rivastach Patch; Rivastigmine transdermal system; SDZ 212713; SDZ ENA 713

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Ono Pharmaceutical
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia
  • Phase III Delirium

Most Recent Events

  • 31 Mar 2019 Ono Pharmaceuticals completes a clinical trial for Alzheimer's-disease in Japan (UMIN000027492)
  • 13 Mar 2019 Novartis and Ono Pharmaceuticals received approvals for Rivastigmine transdermal patch containing a new ingredient the treatment of mild to moderate Alzheimer’s disease dementia in Japan
  • 28 Jan 2019 Juntendo University Urayasu Hospital and Ono Pharmaceuticals completes a clinical trial for Alzheimers disease in Japan (Transdermal) (UMIN000025869)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top